US Biosimilars Take A Bite Out Of Roche's Herceptin, But Tecentriq Surges
Risdiplam Launch Among 2020 Tests
Roche's Q4 and full year results are slightly below expectations, but analysts still see it as one of sector's strong performers in 2020.
You may also be interested in...
CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."
Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.